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During the development of indazolylpyrimidines as novel and potent inhibitors of vascular endothelial growth factor (VEGF)
receptor-2 (VEGFR2) tyrosine kinase, we observed that some human tumour xenografts are more sensitive to VEGFR2 kinase
inhibitors than others. A better understanding of the basis for this differential response may help to identify a predictive marker that
would greatly aid in the identification of a suitable patient population for treatment. One representative compound from the
indazolylpyrimidine series is GW654652 that inhibited all three VEGFRs with similar potency. The inhibition of VEGFR2 kinase by
GW654652 was about 150 to 48800 more potent than the inhibition of eight other kinases tested. GW654652 inhibited VEGF-
and bFGF-induced proliferation in endothelial cells with an IC50 of 110 and 1980nM, respectively, and has good pharmacokinetic
profile in mouse and dog. We investigated the association between VEGF and VEGFR2 expression and the antitumour efficacy of
GW654652, in various xenograft models. Statistically significant associations were observed between the antitumour efficacy of
GW654652 in xenografts and VEGF protein (P¼0.005) and VEGFR2 expression (P¼0.041). The oral dose of GW654652
producing 50% inhibition of tumour growth (ED50) decreased with increasing levels of VEGF (r¼ 0.94); and, in contrast, the ED50
increased with the increased expression of VEGFR2 (r¼0.82). These results are consistent with the observed inverse correlation
between VEGF and VEGFR2 expression in tumours. These findings support the hypothesis that VEGF and VEGFR2 expression by
tumours may predict the therapeutic outcome of VEGFR kinase inhibitors.
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Vascular endothelial growth factor (VEGF) and its receptors have
been implicated in the angiogenesis that is essential for growth and
metastasis of solid tumours. Since formation of solid tumours is
angiogenesis dependent, several strategies have been developed to
inhibit VEGF signal transduction as part of anticancer therapy
(reviewed in McMahon, 2000). These include monoclonal anti-
bodies against VEGF and its receptor, VEGFR2 (vascular
endothelial growth factor receptor-2), as well as VEGF-trap that
also neutralises VEGF in microcirculation (Kim et al, 1993; Holash
et al, 2002). A recombinant humanised monoclonal version of the
anti-VEGF mAb has shown promising results in human cancer
patients (Hurwitz et al, 2003). An alternate approach to block
VEGF signalling is to develop low molecular weight inhibitor of the
tyrosine kinase domain of VEGFR2, suitable for chronic oral
administration and continual suppression of tumour angiogenesis.
Several selective VEGFR2 kinase inhibitors have been developed
and have demonstrated efficacy in xenograft models (Fong et al,
1999; Wood et al, 2000; Laird et al, 2002).
VEGFR2 kinase inhibitors are less effective against some tumour
xenografts than others (Fong et al, 1999; Wood et al, 2000; Laird
et al, 2002). The degree of efficacy of VEGF suppression by an anti-
VEGF antibody or a VEGF-Trap also differs markedly in different
experimental tumours (Kanai et al, 1998; Asano et al, 1999; Rowe
et al, 2000; Kim et al, 2002). With some of the earlier VEGFR2
kinase inhibitors, SU5416 and PTK787/ZK222584, slower growing
tumours were found to be more inhibited by these agents than
faster growing tumours (Fong et al, 1999; Wood et al, 2000). More
recently, Laird et al (2002) concluded that differences in growth
rates were unlikely to be the key determinants of differential
tumour responses to the VEGFR2 kinase inhibitor, SU6668,
because all tumour models examined in the study were fast
growing in vivo. We were interested in a better understanding of
the basis for this differential response to various anti-VEGF
therapies that may help to identify a predictive marker(s) of
response, and would greatly aid in the identification of a suitable
patient population for treatment.
The clinical success of Gleevec/STI-571 was greatly facilitated by
the presence of the Philadelphia chromosome in chronic
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smyelogenous leukaemia as a diagnostic marker and by the ability
to monitor the disease via the analysis of white blood cell counts
(Druker and Lydon, 2000). The oestrogen receptor status of
primary breast cancers has been shown to predict the benefit of
adjuvant tamoxifen in prolonging both disease-free interval and
overall survival (reviewed in Jordan, 2000). Similarly, expression of
Her2 and CD20 antigen was useful in development of Trastuzumab
and Rituxan (McLaughlin et al, 1998; Vogel et al, 2002). Although
several small molecules and protein therapeutics targeting VEGF
signalling have shown encouraging clinical results, clinical
development of VEGFR-targeted therapies has been more challen-
ging due to lack of a suitable diagnostic marker (Kindler et al,
2001; George et al, 2003; Hurwitz et al, 2003; Kuenen et al, 2003;
Raymond et al, 2003; Yang et al, 2003).
Overexpression of VEGF has been shown to correlate with
increased risk of metastatic disease and overall poor prognosis in
different carcinomas (reviewed in Ferrara, 1999). Elevated VEGF
expression has also been used as a marker to select tumour types
in some of the early clinical trials with anti-VEGF therapies.
Vascular endothelial growth factor is abnormally overexpressed in
highly vascular clear-cell renal carcinoma (RCC) due to the
deregulation of VEGF degradation resulting from mutations in the
VHL gene (Iliopoulos et al, 1996). Bevacizumab, a neutralising
mAb to VEGF, significantly prolonged time-to-disease progression
but failed to show an increase in overall survival in patients with
metastatic RCC (Yang et al, 2003). Semaxanib/SU5416, a VEGFR2
kinase inhibitor, demonstrated preliminary evidence of activity in
RCC and mesothelioma patients (Kindler et al, 2001; Kuenen et al,
2003); however, it failed to show clinical benefit in large Ph III
studies in patients with colorectal cancer. Similarly, SU11248 and
PTK787 also showed tumour responses in Ph I studies in RCC
(George et al, 2003; Raymond et al, 2003). A recent Ph III study
with bevacizumab in colorectal cancer patients showed improved
response rate and overall survival when given with standard
chemotherapy (Hurwitz et al, 2003). The prognostic value of VEGF
and its receptors in relation to anti-VEGF therapies, however, has
not been studied as widely.
The present study describes a novel and selective VEGFR2
kinase inhibitor, GW654652 (Kumar et al, 2003; Cheung et al,
2003) and the association between its antitumour efficacy and the
expression of VEGF and VEGFR2 in various xenograft models. We
observed that the elevated expression of VEGF in tumour models is
associated with the increased sensitivity to GW654652. Moreover,
expression of VEGF was inversely related to VEGFR2 expression in
tumour xenografts, which is consistent with the published
observations that VEGF downregulates VEGFR2 expression by
turnover of receptor at the cell surface.
MATERIALS AND METHODS
Materials
Human tumour cell lines SW620, HT29, HCT116 (colon carcino-
ma), A375P (melanoma), and PC3 (prostate adenocarcinoma) were
obtained from the American Type Culture Collection (Rockville,
MD, USA). HN5, human head & neck carcinoma cells, were kindly
provided by Helmout Modjtahedi at the Institute of Cancer
Research, Surrey, and UK. Human umbilical vein endothelial cells
(HUVEC) were obtained from Clonetics (San Diego, CA, USA).
GW654652, N
2-[5-(ethylsulphonyl)-2-methoxyphenyl]-N
4-methyl-
N
4-(3-methyl-1H-indazol-6-yl)pyrimidine-2,4-diamine;
GW612286, N
4-(3-methyl-1H-indazol-6-yl)-N
2-(3,4,5-trimethoxy-
phenyl)pyrimidine-2,4-diamine; and GW695612X, 4-chloro-3-({4-
[methyl(3-methyl-1H-indazol-6-yl)amino]pyrimidin-2-yl}amino)-
benzenesulphonamide were synthesised at GlaxoSmithKline
(Durham, NC, USA) (Table 1). Human and mouse VEGF Elisa
kits were obtained from R&D Systems (Minneapolis, MN, USA).
Kinase assays
Vascular endothelial growth factor receptor kinase assays were
carried out in a homogenous time-resolved fluorescence (HTRF)
format in 384-well microtitre plates using a purified, baculovirus-
expressed GST-fusion protein encoding the catalytic carboxyl-
terminus of human VEGFR kinase 1, 2, or 3. Reactions were
initiated by the addition of 10ml of activated VEGFR kinase (1nM,
0.1 M HEPES pH 7.5, 0.1mgml
 1 BSA, and 0.30mM DTT) to 10ml
of substrate (360nM biotin-aminohexyl-EEEEYFELVAKKKK-NH2
peptide, 75mM ATP, 10mM MgCl2) and 1ml of small molecule
inhibitor at various concentrations. Plates were incubated at room
temperature for 60min, and the reaction was stopped by the
addition of 20ml 100mM EDTA. Homogenous time-resolved
fluorescence reagents (20ml1 5 n M streptavidin-linked allophyco-
cyanin, 1nM europium-labelled anti-phosphotyrosine antibody in
0.1 M HEPES, pH 7.5, 0.1mgml
 1 BSA) were added and plates were
incubated for a minimum of 10min. The fluorescence at 665nm
was measured with a Victor plate reader (Wallac, Shelton, CT,
USA) using a time delay of 50ms. The data for dose responses were
plotted as % inhibition calculated with the data reduction formula:
100 (1 (U1 C2)/(C1 C2)) vs concentration of compound
where U is the unknown value, C1 is the average control value
obtained for 1ml DMSO, and C2 is the average control value
obtained for 0.035 M EDTA. Data were fitted with a curve described
by: y¼((Vmax x)/(Kþx)þY2), where Vmax is the upper
asymptote, Y2 is the Y intercept, and K is the IC50.
Table 1 Enzyme and cellular potency of VEGFR2 kinase inhibitors
Compound GW654652 GW612286 GW695612
VEGFR2 IC50(nM) 2.3 8 1.1
HUVEC-VEGF IC50(µM) 0.11 0.18 0.26
HUVEC-bFGF IC50(µM) 1.98 3.63 3.84
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IC50 of various small molecules were determined against human VEGFR2 kinase as well as HUVEC grown in presence of VEGF or bFGF as described in Materials and
Methods. HUVEC¼human umbilical vein endothelial cells; VEGFR¼vascular endothelial growth factor (VEGF) receptor; IC¼inhibitory concentration.
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sInhibition of several other kinases by small molecules was also
determined. Each kinase assay was conducted using purified
recombinant catalytic domain of the enzyme. The concentration of
ATP and kinase-specific biotinylated peptide in each assay was
below the apparent Km of the respective substrate. Inhibition of c-
Fms, SRC, and Tie-2 was evaluated by an HTRF format and the
inhibition of CDK2, CDK4, EGFR, ErbB2, and Eph-B4 was detected
by scintillation proximity assay.
Cellular proliferation assays
Effect of kinase inhibitors on cell proliferation was measured using
BrdU incorporation method using commercially available kits
(Roche Diagnostics, Indianapolis, IN, USA). Briefly, HUVEC were
seeded in a medium containing 5% FBS in type 1 Collagen-coated
96-well plates and incubated overnight at 371C, 5% CO2. The
medium was aspirated from the cells, and various concentrations
of kinase inhibitors in serum-free medium were added to each
well. After 30min, VEGF (10ngml
 1) or bFGF (0.3ngml
 1) was
added to the wells. Cells were incubated for an additional 72h and
BrdU (10mM) was added during the last 18–24h of incubation.
Data were fitted with a curve described by the equation,
y¼Vmax (1 (x/(Kþx))), where K is equal to the IC50.
Tumour xenografts
Tumours were initiated by injection of tumour cell suspension
subcutaneously in 8–12-week-old nude mice, except PC3 tumours
that were grown in SCID mice (Charles River Laboratories,
Wilmington, MA, USA). When tumours reached a volume of
100–200mm
3, mice were randomised into groups of eight prior to
treatment with VEGFR kinase inhibitors. Animals were treated
with kinase inhibitors (10, 30, or 100mgkg
 1) or vehicle (0.5%
hydroxypropyl methyl cellulose, 0.1% Tween 80 in sterile water),
administered once or twice daily by oral gavage for 2–3 weeks (till
the mean tumour volume reached 1000–1500mm
3). Tumour
volume was measured twice weekly by calipers, using the formula
(length width width 0.5), where length was the longest
diameter across the tumour, and width was the corresponding
perpendicular. Tumour growth inhibition was calculated by
change in the slopes of tumour growth for control and treated
tumours. The oral dose of GW654652 producing 50% inhibition of
tumour growth (ED50,m g k g
 1) was estimated by a programme
that performed a weighted nonlinear regression analysis of data
using the equation: y¼Vmax(1 (x/(Kþx))), where K is equal to
ED50. All animal studies were carried out with the appropriate
institutional ethical committee approval and they met the
standards of both the US federal regulations and those required
by the UKCCCR guidelines (Workman et al, 1998).
Staining of tumour cells for flow cytometry
Freshly excised tumours (400–800mm
3) were dissociated into
single-cell suspension by enzymatic digestion with DNAse and
collagenase. Cells were fixed and permeabilised with LeucoPerm
(Serotec, Kidlington, UK) and labelled for 30min at 41C with anti-
FLK-1 antibody (clone A-3, SantaCruz, CA, USA). Cells were then
incubated with goat anti-mouse-biotin antibody followed by
streptavidin-FITC. Labelled cells were analysed with an FACSort
(Becton Dickinson, San Jose, CA, USA) and the percentage of
VEGFR2-positive cells and channel differences were determined
using CellQuest software.
Western blot analysis of VEGFR2
Snap-frozen tumour xenograft tissues were lysed in RIPA buffer
(150mM NaCl, 50mM Tris, 1% NP-40, 0.25%. Na-deoxycholate,
0.1% SDS, 1mM sodium fluoride, 1mM fresh sodium orthovana-
date, and protease inhibitors). Protein concentrations were
determined using a BCA kit, and 120–200mg of tumour extract
was loaded onto a 3–8% Tris-acetate gel. To quantitate the
VEGFR2 expressions in lungs, 25mg of lung extracts (obtained by
lysing frozen lung samples from Swiss nude female mice injected
with VEGF121 (R&D Systems) was loaded onto a 3–8% Tris-acetate
gel. Proteins were transferred to nitrocellulose membranes.
Membranes were blocked for 1h in TBS (25mM Tris-HCl, pH
7.4, 150mM NaCl, 2.7mM KCl) containing 5% (w/v) low-fat milk.
Membranes were then probed with a VEGFR2-specific anti-Flk1
antibody (crossreacts with both mouse and human VEGFR2; clone
A-3, Santa Cruz), followed by a donkey anti-mouse-HRP antibody.
ECL (Amersham) was used for detection, and densitometric
analysis of receptor expression was carried out using a BioRad
Fluor-S MultiImager). To confirm equal protein loading, mem-
branes were stripped and reprobed with antibody against
b-tubulin (Santa Cruz).
Vascular endothelial growth factor levels in xenograft
tumours
Human and mouse VEGF levels in tumour extracts were
determined by an immunoassay, according to the manufacturer’s
instructions (R&D Systems). Samples were analysed by serial
dilution and tests were performed at least in duplicates. Vascular
endothelial growth factor levels were normalised relative to the
protein concentration of the tumour extracts. Circulating human
and mouse VEGF levels in plasma were also determined using the
same assay.
Statistical analysis
Spearman’s nonparametric test was used to investigate the
association between quantitatively measured VEGFR2 expression,
VEGF expression, and the antitumour efficacy of GW654652.
RESULTS
Antitumour efficacy
In an effort to identify a suitable VEGFR kinase inhibitor for
clinical development, several potent VEGFR2 kinase inhibitors
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Figure 1 Growth inhibition of human tumour xenografts in mice treated
with VEGFR2 kinase inhibitors, GW654652, GW612286, or GW695612.
Animals with 100–200mm
3 tumour volume were randomly assigned to
either vehicle or treatment group (n¼8 mice group
 1) as described in
Materials and Methods. All compounds were administered orally at
30mgkg
 1 once daily, except GW695612 (30mgkg
 1, twice day
 1). Data
represent tumour growth inhibition (mean7s.e.m.) in drug-treated animals
compared to vehicle-treated mice after 21 days of dosing.
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sfrom indazolylpyrimidine series were tested in multiple human
tumour xenograft models. Different human tumour xenografts
exhibited varying levels of sensitivity to the VEGFR2 kinase
inhibitors. Invariably, HN5 and HT29 xenografts showed greater
growth inhibition, while A375P and PC3 xenografts demonstrated
much lower growth inhibition using multiple compounds at the
same dose and schedule. To illustrate this point, antitumour data
from three different VEGFR2 kinase inhibitors administered at
30mgkg
 1 (orally, once, or twice daily) is shown in Figure 1.
Tumour models HT29 and HN5 were extremely sensitive, as these
compounds inhibited tumour growth by 50–70% at this dose. In
contrast, PC3 and A375P models were less sensitive (5–20%
inhibition) to the VEGFR2 kinase inhibitors at the same dose
(Figure 1). Chemical structure, VEGFR2 enzyme activity, and
antiproliferative activity against HUVEC growing in presence of
VEGF or bFGF for the three compounds are summarised in Table 1.
To further confirm and extend these observations, a more
detailed antitumour efficacy study with GW654652 in six different
human xenografts was conducted. GW654652 was picked for these
studies because of its good pharmacokinetic profile in mouse and
dog. GW654652 inhibits all three VEGF receptor kinases with an
IC50 ranging from 2 to 12nM (Table 2). The inhibition of VEGFR2
kinase by GW654652 was about 150 to 48800 more potent than
the inhibition of eight other kinases tested (Table 2). The potent
and selective inhibition of VEGFR kinases by GW654652 is also
reflected in the potent cellular efficacy against HUVEC stimulated
with VEGF compared to bFGF (Table 1). GW654652 has very little
effect on the growth of human foreskin fibroblasts or various
tumour cell lines in culture (IC50 ranging from 4 to 410mM).
The pharmacokietics and antitumour activity of GW654652 were
evaluated in mice at 10, 30 and 100mgkg
 1 dose administered
orally on a once day
 1 schedule. An oral dose of 10, 30, and
100mgkg
 1 of GW654652 resulted in free Cmax (based on 99%
protein binding and total plasma concentration) of 0.06, 0.23, and
1.38mM, respectively. The plasma concentration remained above
the IC50 for VEGF-induced HUVEC proliferation for 0, 2, and 12h
for 10, 30, and 100mgkg
 1 doses, respectively. GW654652 was a
potent inhibitor of the HT29, HCT116 and HN5 xenografts with an
ED50 ranging from 20 to 28mgkg
 1. However, the inhibition of
SW620, PC3, and A375P models was less pronounced with an ED50
ranging from 46 to 114mgkg
 1 dose (Table 3, Figure 2A).
Correlation of VEGF expression with antitumour activity
of GW654652
The differential response of the tumours to VEGF/VEGFR
antagonists may be due to differences in the levels of either the
ligand or the receptor in these tumours. Concentrations of mouse
Table 2 Inhibition of various protein kinases by GW654652
IC50 (lM)
a
Fold selectivity vs
VEGFR-2
b
VEGFR-2 0.002370.0008 —
VEGFR-3 0.002570.0005 1.1
VEGFR-1 0.012070.0026 5.3
SRC 0.3570.24 156
Eph-B4 0.4670.03 204
c-Fms 0.5370.33 237
Tie2 0.3270.04 144
EGFR 1.3670.42 605
ErbB2 11.5372.74 5125
CDK2 420 48800
CDK4 420 48800
aValues are mean7s.e.
bRatio for the IC50 obtained with a given kinase compared to
that achieved vs VEGFR-2. VEGFR¼vascular endothelial growth factor receptor;
IC¼inhibitory concentration.
Table 3 Inhibition of tumour growth by GW654652, a VEGFR kinase
inhibitor
% Inhibition
a
10mgkg
 1 30mgkg
 1 100mgkg
 1 ED50
(mgkg
 1day
 1)
HT29 5 69 98 2078
HCT116 18 59 71 2178
HN5 24 46 83 28710
SW620 12 44 74 46711
PC3 ND
b 21 48 108750
A375P ND
b 14 49 114754
a% Inhibition of tumour growth compared to vehicle-treated animals.
bNot
detectable. VEGFR¼vascular endothelial growth factor receptor.
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Figure 2 Relationship between (A) inhibition of tumour growth by
GW654652, (B) human VEGF expression, and (C) VEGFR2 expression in
human tumour xenografts. All values of VEGF levels (ELISA) and VEGFR2
expression (represented as Md: mean channel difference from FACS
analysis) are mean7s.e. and were obtained by analysing 4–15 tumour
samples.
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sand human VEGF in the tumours and in circulation were
measured in the human xenografts. Mouse VEGF levels were very
similar in different tumour models and probably are not the major
determinants of the differential response to VEGFR2 kinase
inhibitors. Median circulating mouse VEGF levels ranged from
59 to 94pgml
 1 in plasma of mice with and without various
tumour xenografts and the tumour content ranged from 12 to
28ngmg
 1 protein in different models. No detectable circulating
hVEGF was found (detection limit 4pgml
 1). In contrast, very
high and variable levels of hVEGF in different tumour models were
observed. The levels of hVEGF varied from 93ngmg
 1 of A375P
tumour protein to 1710ngmg
 1 of HT29 tumour protein
(Figure 2B). Relative abundance of hVEGF mRNA correlated well
with the protein content of the tumour tissues (data not shown). A
comparison of antitumour activity of GW654652 with the hVEGF
levels suggested that the oral dose of GW654652 producing 50%
inhibition of tumour growth in mice decreased with the increasing
concentrations of hVEGF in the tumours (Figures 2A and B).
Statistically significant inverse correlation between hVEGF protein
expression and the dose of GW654652 that produces 50%
inhibition of human tumour xenografts was observed (r¼ 0.94,
P¼0.005).
Correlation of VEGFR2 expression with antitumour
activity of GW654652
The VEGFR2 protein expression in tumour xenografts was
analysed by flow cytometry using single-cell suspensions from
freshly harvested tumour tissue (Ziegler et al, 1999). The FACS
data for four or five different tumour samples for each xenograft
was collected in four-decade mode, gated for single cells, analysed
to calculate the mean channel difference (Md), which represents
the magnitude of difference between VEGFR2-specific staining and
nonspecific isotype staining. Figure 2C depicts the mean values
and s.e.m. for each xenograft. Histograms showing fluorescence
intensities of VEGFR2 for a representative tumour sample of each
xenograft are shown in Figure 3B. The VEGFR2 expression was
higher in PC3, SW620, and A375P tumours compared to other
xenografts tested (Figures 2C and 3B).
In agreement with these FACS results, Western blot analysis of
PC3 and A375P tumour extracts also showed readily detectable
protein bands of VEGFR2 which were absent or barely detectable
in HT-29, HCT-116, and HN5 tumours (Figure 3A). Multiple
VEGFR2 protein bands that may correspond to different
glycosylated forms of human VEGFR2 expressed by the tumour
cells and mouse VEGFR2 expressed by the host endothelial cells
were observed in PC3 and A375P tumours. For comparison
purposes, human VEGFR2 from HUVEC and the mouse VEGFR2
from mouse lungs analysed on a separate gel are shown in
Figure 3A. Although PC3 xenograft express the highest level of
VEGFR2 protein followed by A375P melanoma xenograft, the
relative intensities of the hVEGFR2 and mVEGFR2 protein bands
in PC3 and A375P tumours were not quantified due to the
comigration of the two forms on the gel (Figure 3A).
A comparison of antitumour activity of GW654652 with the
VEGFR2 expression revealed that the oral dose of GW654652
producing 50% inhibition of tumour growth in mice increased in
rank order with the increasing levels of VEGFR2 in the tumours
(Figures 2A and C). A statistically significant association was also
seen between antitumour activity of GW654652 and VEGFR2
expression by tumour xenografts (r¼0.82, P¼0.041).
Modulation of VEGFR2 by VEGF in vivo
A strong inverse correlation between VEGF levels and the VEGFR2
expression among various xenografts was also observed
(r¼ 0.85, P¼0.016; Figures 2B and C). Thus, we examined the
effect of VEGF on VEGFR2 expression in vivo. Since lung tissue
contain high amounts of endothelial cell expressing VEGFR2, we
looked at the direct effects of recombinant human VEGF121 on the
VEGFR2 levels in murine lungs. After the intravenous injection of
VEGF121 in mice, the lungs were collected after 5, 10, and 15min,
and the VEGFR2 levels were determined by Western blots. The
receptor levels decreased as a function of time in mice injected
with VEGF121 compared to untreated (data not shown) or vehicle-
treated animals (Figure 4). These results are consistent with the
earlier observations of Wang et al (2000) showing that the cell
surface expression of VEGFR2 is regulated by VEGF in cultured
endothelial cells.
Figure 3 Expression of VEGFR2 by human tumour xenografts. (A)
Western blot analysis of VEGFR2 in tumour extracts. The amount of
protein analysed for PC3¼120mg, A375P¼200mg, HCT116¼180mg,
HT29¼200mg, and HN5¼200mg. (B) Expression of VEGFR2 by human
tumour xenografts. FACS analysis of VEGFR2 expression in PC3, SW620,
A375P, HN5, HCT116, and HT29 tumours dissociated as single-cell
suspensions. The fluorescence profiles of cells treated with VEGFR2
antibody (solid line) and isotype controls (dotted line).
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sDISCUSSION
Patients whose tumours produce high levels of VEGF or other
markers of aggressive neovascularisation have significantly poor
prognosis with respect to disease progression as well as survival
(reviewed in Ferrara, 1999). Increased expression of VEGF in
certain carcinomas leads to the development of highly vascularised
tumours. Consequently, it has been hypothesised that an inhibitor
of VEGF signalling would be particularly efficacious in inhibiting
tumour growth in the patients that overexpress VEGF (Mendel
et al, 2000). However, a clear relationship between increased VEGF
expression and the efficacy of anti-VEGF therapy is not yet
established. In this study, we present data that show significant
associations between the antitumour efficacy of GW654652, a
novel and selective VEGFR2 inhibitor, and VEGF protein in
xenografts. The tumours that produce higher levels of VEGF were
inhibited more effectively by GW654652 and required lower oral
doses of the compound to produce 50% inhibition of tumour
growth (Figure 2; r¼ 0.94, P¼0.005). High levels of VEGF
expression alone are capable of initiating angiogenesis in a
quiescent tumour vasculature; however, many other factors are
also involved in angiogenic switch and maturation of tumour
vasculature (Bergers and Benjamin, 2003). In agreement with these
observations, our data suggest that VEGF is the major determinant
of tumour growth but certainly do not rule out the possibility that
other factors may also be involved in determining the sensitivity of
the tumours to a VEGFR2 inhibitor. Data from the SW620
xenograft that has low VEGF and high VEGFR2 but reasonable
sensitivity to the VEGFR2 kinase inhibitor are consistent with this
hypothesis (Figure 2).
Interestingly, we also observed that the tumours with increased
VEGF expression have lower levels of VEGFR2 expression (Figures
2B and C). Others have observed that under normal physiological
conditions VEGF modulates VEGFR2 by downregulating cell
surface expression of VEGFR2 in cultured endothelial cells (Wang
et al, 2000). We examined the effect of VEGF on VEGFR2
expression in vivo and demonstrated that the VEGFR2 receptor
levels decreased significantly as a function of time in lungs from
animals injected with VEGF (Figure 4). An interesting inverse
association between VEGF and VEGFR2 and overall survival in
CLL patients has also been observed (Aguayo et al, 2000; Ferrajoli
et al, 2001). Our data support the hypothesis that VEGF negatively
regulates VEGFR2 expression and the tumours that produce low
levels of VEGF show elevated VEGFR2 expression and decreased
sensitivity to VEGFR2 kinase inhibitors (Figure 2).
Conversely, others have proposed that high level of VEGF
receptor expression by tumour cells can also negatively modulate
VEGF signalling by sequestering VEGF, which otherwise will bind
to the receptors expressed by vascular endothelial cells (Hiratsuka
et al, 1998; Kearney et al, 2002). Vascular endothelial growth factor
receptors are in most cases specifically expressed on vascular
endothelial cells, but certain tumour cells also express VEGFR2
(Masood et al, 1997; Dias et al, 2000; Masood et al, 2001; Podar
et al, 2001; Strizzi et al, 2001; Jackson et al, 2002; Nakopoulou et al,
2002). The expression of VEGFR2 by tumour cells may be a
mechanism to become less dependent on VEGF signalling for
tumour angiogenesis as well as to negatively regulate the VEGF
expression (Hiratsuka et al, 1998; Kearney et al, 2002). Consistent
with this hypothesis, the two tumours PC3 and A375P, which
express very high levels of human tumour VEGFR2 as determined
by Western blots and mRNA analysis also express very low levels
of VEGF (Figure 2 and data not shown).
The reasons why the elevated expression of VEGFR2 in tumours
is associated with the decreased sensitivity to VEGFR inhibitors
are unknown. However, others have demonstrated that the
decreased activity of an anticancer agent could also stem from
an increased expression of the target enzyme, in addition to other
mechanisms. Elevated expression of thymidylate synthase (TS)
protein as a result of gene amplification has been described in
tumour cells selected in vitro and in vivo for drug resistance by
exposure to fluoropyrimidine cytotoxic drugs (Berger et al, 1985;
Clark et al, 1987). In fact, TS activity has been associated with
response to 5-FU in a number of human cancers, and patients with
low TS levels were more likely to respond compared to patients
with high TS levels (Kornmann et al, 1997; Allegra et al, 2003).
Similarly, the inefficiency of chemotherapy with the antifolate
methotrexate can also stem from an increased expression of
dihydrofolate reductase (Alt et al, 1978).
Our present results indicate that tumours producing higher
levels of VEGF elicit decreased expression of VEGFR2 and
increased sensitivity to a VEGFR2 kinase inhibitor. The inverse
relationship between the VEGF expression and the VEGFR2
expression is consistent with the hypothesis that VEGF modulates
VEGFR2 by downregulating cell surface expression of VEGFR2 in
tumours. These results suggest that VEGFR kinase inhibitors may
be more effective in patients with tumours expressing high VEGF
and low VEGFR2. Future clinical trials should investigate whether
expression of VEGF or VEGFR2 in tumour biopsies from patients
receiving VEGFR2 kinase inhibitors can be used as diagnostic
markers for VEGF-targeted therapies.
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